OCC is in the process of connecting with patients who may have participated in the Phase 3 KEYNOTE-B96 trial (NCT05116189), also known as ENGOT-ov65. We are interested in interviewing patients who have firsthand experience with the therapy used during that trial.
The trial studied KEYTRUDA (pembrolizumab)/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer.
If you participated in the trial and/or you have experience with this specific therapy and would be interested in being interviewed by Alexandria, OCC's Lead, Government Relations and Advocacy please contact me directly at:
atadman@ovariancanada.org
#OCCinfoandupdates
-------------------------------------------